Close Menu

A*Star

The Singapore-based firm has established a US subsidiary and named distributors to sell its products across Europe, the Middle East, and Asia.

The technology relates to the isolation and genetic analysis of circulating fetal cells from maternal blood.

The first assay to be developed under the new five-year strategic partnership is a solid biopsy breast cancer assay designed to guide drug selection.

Each panel that the collaborators develop is expected to be highly multiplexed and syndromic, addressing clinically important infectious diseases in Asia.

GUSTO study researchers said maternal lifestyle, fetal genetic, and fetal epigenetic factors affect birth weight and early childhood adiposity.

While gain-of-function mutations lead to congenital arhinia, inactivating mutations lead to an adult-onset muscular dystrophy, the researchers reported.

The partners will collaborate in developing Atreca's single-cell sequencing technology to advance new cancer immunotherapies.

Members of the Genome 10K Consortium sequenced the genome of the ocean sunfish, Mola mola, comparing it to sequences from pufferfish and other related species.

The mass spectrometry instrument maker will provide A*Star's Bioprocessing Technology Institute with expertise and access to a Synapt G2-S instrument.

Singapore plans to spend $13.2 billion on research and development between 2016 and 2020.

Pages

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.